Business Wire

Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients

Share

Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that it will present new data from ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS 2020), taking place virtually December 8-11, 2020.

These data, which build upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to consistently inform optimal treatment planning, highlight Agendia’s many trials in progress that will ultimately impact patient treatment and outcomes.

Specific data selected for poster spotlight discussions include:

  • BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
    Authors: Krop, I., et al.
    Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
    Poster #: PD3-01
  • 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
    Authors: Whitworth, P., et al.
    Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
    Poster #: PD9-01

In addition, Laura van’t Veer, PhD, co-founder and Chief Research Officer at Agendia, will be giving an oral presentation on an abstract entitled “How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status.”

“The MammaPrint and BluePrint assays give patients with breast cancer and their healthcare providers the precise information they need to determine which treatment approach is the most targeted and effective for their situation,” says William Audeh, MD, MS, Chief Medical Officer at Agendia. “Our continued efforts to identify and understand the biologic drivers of breast cancer in large patient populations have also enabled us to look within these to study unique subsets of people, and to offer additional important insights, as we continue to expand knowledge in breast cancer and build a library of data that will be of benefit to patients.”

Following are details of additional Agendia abstracts that have been accepted for SABCS 2020:

  • How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
    Authors: van’t Veer, L.J., et al.
    Session: General Session 4 | Friday, December 11, 2020 | 8:45am – 11:30am CST
    Poster #: PS6-01
    Presentation #: Oral Presentation GS4-11 | Presentation 11:15am-11:25am CST | Live Q&A Session 11:25am-11:30am CST
  • Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
    Authors: Whitworth, P., et al.
    Session: Poster Session 4
    Poster #: PS4-04
  • The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.
    Authors: Noordhoek, I., et al.
    Session: Poster Session 6
    Poster #: PS6-06
  • Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
    Authors: McKelley, J., et al.
    Session: Poster Session 6
    Poster #: PS6-19
  • MammaPrint and BluePrint as prognostic indicators for elderly patients with early stage breast cancer
    Authors: Blumencranz, P.W., et al.
    Session: Poster Session 6
    Poster #: PS6-41
  • Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients
    Authors: Sharma, D., et al.
    Session: Poster Session 7
    Poster #: PS7-68
  • Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients
    Authors: Chen, M., et al.
    Session: Poster Session 7
    Poster #: PS7-69
  • Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients
    Authors: Crozier, J., et al.
    Session: Poster Session 14
    Poster #: PS14-11
  • Differential gene expression in Luminal-type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
    Authors: Lesnikoski, B., et al.
    Session: Poster Session 18
    Poster #: PS18-03
  • Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
    Authors: Kaklamani, V.G., et al.
    Session: Poster Session 18
    Poster #: PS18-05
  • The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
    Authors: Lee, L., et al.
    Session: Ongoing Trials Posters
    Poster #: OT-12-01

These data underscoreAgendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.

Please follow us on our Twitter, Facebook and LinkedIn pages for unique content we will be sharing throughout SABCS.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens with results in as little as 5-7 days to inform pre- and post-operative treatment decisions. For more information on our assays and our ongoing trials, please visit www.agendia.com.

Contact information

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Towerco Valocîme uses Sitetracker to gain operational efficiency and enable the more fair Towerco business model of Valocîme in France and Europe2.12.2020 08:00:00 CETPress release

Sitetracker, the global standard for managing high-volume projects for infrastructure owners and operators like Ericsson, British Telecom, Vertical Bridge, and Vodafone/Vantage Towers, is proud to announce their partnership with Towerco Valocîme, an innovative Tower company in France. The current distribution of the telecoms value chain is strongly unbalanced in favor of towercos. The purpose of Towerco Valocîme's offers is to rebalance in favor of owners and operators. At the end of 2019, more than 1,000 landlords had signed the Towerco Valocîme offers allowing them to increase their income significantly. In 2020, Towerco Valocîme has launched its operator offers to reduce their hosting costs and thus increase their average operating income per site. “We have created a fair and simple model for towers in France,” said Frédéric Zimer, CEO of Towerco Valocîme. He continued, “We have thousands of landlords and now we are bringing in operators. The key to maintaining our margins is operat

Deenova Bolsters Its 2020 Market Momentum in Pharmacy Automation With Entry Into Poland2.12.2020 08:00:00 CETPress release

Deenova announced today that in continuing its meteoric 2020 business boom, it made its first foray into Eastern Europe with new contracts for delivery of its market leading pharmacy robots and related technologies to Greater Poland Children's Health Centre in Poznań, with Polish leading equipment company MEDIM in Piaseczno. Piotr Młynarczyk, MEDIM General Manager, stated: “After a long search on a competitive sales process that thoroughly searched all options for pharmacy unit dose robots, I am very proud to select Deenova for partnership in the project at Greater Poland Children's Health Centre in Poznań. We chose Deenova solutions, mainly because of their unique technology and business approach to R.O.I.” Christophe Jaffuel, Deenova Chief Commercial Officer, added: “I am extremely excited to have been selected by Greater Poland Children's Health Centre in Poznań, and Poland medical technology leader MEDIM, especially after their extensive experience comparing and contrasting Deenova

Yokogawa and Power Factors Announce Reseller Agreement for Renewable Energy Asset Performance Management Platform2.12.2020 03:00:00 CETPress release

Yokogawa Electric Corporation (TOKYO: 6841) and US-based Power Factors, LLC, announce a global reseller agreement under which Yokogawa will market Power Factors’ industry-leading Drive software platform of asset performance management (APM) solutions for renewable power facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005653/en/ Power Factor’s Drive platform for asset performance management (Graphic: Business Wire) Designed for solar, wind, and energy storage assets, Power Factors’ cloud-based Drive platform for APM delivers the tools and insights needed to optimize the levelized cost of energy (LCOE*) and address the complex integration of large, diverse fleets of renewable energy assets. The platform empowers owners and operators to overcome their biggest challenges, from dealing with aging control technology and disparate systems to the management of data quality, asset performance, and regulatory complian

LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor2.12.2020 00:00:00 CETPress release

LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TT-01025, a novel SSAO/VAP-1 inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) and other inflammatory diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201006171/en/ LG Chem will initiate the Phase 1 clinical trial at PPDLas Vegas Clinical Research Unit in Las Vegas, NV, United States to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TT-01025 in healthy subjects. The trial is expected to be initiated in the first quarter of 2021. “As liver manifestation of a metabolic disorder, NASH is a potentially life threatening condition which increases cardiovascular risk and can lead to

Anark Deepens Commitment to Customer Engagement with Additions to Executive Leadership Team, Marketing, and Sales Enablement1.12.2020 20:51:00 CETPress release

Anark Corporation, a leading provider of Intelligent Information Management (IIM) and collaboration software, announced today that Greg Caldwell, former marketing executive at 3D Systems and Microsoft, has joined as Vice President of Marketing and Sales Enablement. Caldwell will join the executive leadership team and be responsible for elevating Anark’s global brand, expanding market opportunity, and growing the business. Caldwell is a seasoned marketer, strategist, and business leader with an extensive background in IT hardware, software, and manufacturing. Throughout his career he has always believed in putting the customer first and creating modern, relevant, digital initiatives that help customers educate themselves and make more informed buying decisions. Prior to joining Anark in November of 2020, Caldwell was Vice President of Marketing and Communications at 3D Systems, one of the world’s leading additive manufacturing companies. Before 3D Systems, he spent almost 11 years as Gl

Lineage Logistics Enters the Polish Cold Storage Market With the Acquisition of Pago Sp. z o.o.1.12.2020 18:04:00 CETPress release

Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced it has acquired Pago Sp. z o.o. (“Pago”), a leading warehousing, distribution and transport logistics provider in Poland from its current ownership, including Tönnies International Holding GmbH (“Tönnies”). The strategic acquisition marks the Company’s entrance into the Polish market and adds six exceptional assets to Lineage’s global network of temperature-controlled facilities. Lineage was founded and continues to be managed by Bay Grove Capital, LLC (“Bay Grove”), a principal investment firm dedicated to partnering with strong management teams to build long-term platform investments. Financial terms of the transactions were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005951/en/ The acquisition of Pago Sp. z o.o